Amgen (AMGN) November volatility elevated into denosumab data
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) is recently down $1.24 to $54.76. Phase three data of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
